{"type":"trials","record":{"id":25,"source_id":"clinicaltrials-gov","external_id":"NCT02642094","title":"Aging Mammary Stem Cells and Breast Cancer Prevention","brief_summary":"To examine whether rapamycin can reduce malignant markers and aberrant mammary stem/progenitor cells (MaSCs) number in surgical specimens","overall_status":"Terminated","phases":["PHASE2"],"study_type":"INTERVENTIONAL","sponsor":"LuZhe Sun","enrollment":58,"countries":["United States"],"start_date":"2016-07-01","completion_date":"2022-05-01","last_update_date":"2023-12-05","source_url":"https://clinicaltrials.gov/study/NCT02642094","editorial_summary":"A registered PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Terminated. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-14T02:44:58.543517+00:00","last_seen_at":"2026-09-15T00:18:31.508+00:00","metadata":{"acronym":null,"organization":"The University of Texas Health Science Center at San Antonio","source_has_results":true},"controlled_terms":[],"relevance_confidence":68,"source_quality_score":100,"freshness_score":65,"publication_state":"published","match_explanation":"Published automatically with 68% topic confidence after controlled-term evaluation.","quality_checked_at":"2026-09-15T02:15:56.576005+00:00","duplicate_cluster_key":"registry:nct02642094","duplicate_of_id":null,"clinical_trial_topics":[{"topic_slug":"rapamycin","is_published":true,"match_reasons":["Legacy trial evaluated automatically against controlled title, summary, and longevity-context rules."],"matched_fields":["abstract"],"relevance_score":68,"intelligence_topics":{"name":"Rapamycin","slug":"rapamycin"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/25","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}